Seikagaku To Begin Clinical Trials Of Injectable Hyaluronic Acid Gel For Knee Osteoarthritis Treatment In US
Main Category: Arthritis / RheumatologyArticle Date: 24 Jul 2006 - 0:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
4.6 (5 votes) |
| Healthcare Prof: |  |
3.33 (3 votes) |
Seikagaku, a Tokyo company specializing in the study of intra-articular injection of hyaluronic acid, will begun conducting phase III clinical trials of Gel-200, a new hyaluronic acid gel for intra-articular injection in knee osteoarthritis patients, in the US in August.
The new gel is expected to have a highly analgesic effect with only one shot. In the US, Seikagaku has marketed injectable hyaluronic acid gel under the Supartz brand name since 2001, and currently claims a 20% share of the market.
Seikagaku hopes that the new drug will help expand its market share further since it requires just one injection compared with multiple injections required of Supartz.
The company will bring the new drug to market within four years.
By jcn, JCN Staff Writer
Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.
JCN
Visit our arthritis / rheumatology section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/47909.php>
APA
http://www.medicalnewstoday.com/releases/47909.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
